185 related articles for article (PubMed ID: 33976366)
1. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
2. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Asangani IA; Ateeq B; Cao Q; Dodson L; Pandhi M; Kunju LP; Mehra R; Lonigro RJ; Siddiqui J; Palanisamy N; Wu YM; Cao X; Kim JH; Zhao M; Qin ZS; Iyer MK; Maher CA; Kumar-Sinha C; Varambally S; Chinnaiyan AM
Mol Cell; 2013 Jan; 49(1):80-93. PubMed ID: 23159737
[TBL] [Abstract][Full Text] [Related]
4. The role of NSD2 and EZH2 in the pathogenesis of endometrial carcinoma.
Sun S; Huang DW; Huo LT; Li PL
J Biol Regul Homeost Agents; 2019; 33(4):1233-1239. PubMed ID: 31332986
[No Abstract] [Full Text] [Related]
5. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
6. Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.
Zhang Y; Yan L; Yao W; Chen K; Xu H; Ye Z
Med Sci Monit; 2019 Jan; 25():193-239. PubMed ID: 30616239
[TBL] [Abstract][Full Text] [Related]
7. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
[No Abstract] [Full Text] [Related]
8. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
[TBL] [Abstract][Full Text] [Related]
11. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
Wu X; Scott H; Carlsson SV; Sjoberg DD; Cerundolo L; Lilja H; Prevo R; Rieunier G; Macaulay V; Higgins GS; Verrill CL; Lamb AD; Cunliffe VT; Bountra C; Hamdy FC; Bryant RJ
Prostate; 2019 Jul; 79(10):1079-1089. PubMed ID: 31104332
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Gao B; Liu X; Li Z; Zhao L; Pan Y
Front Oncol; 2020; 10():600514. PubMed ID: 33665162
[TBL] [Abstract][Full Text] [Related]
13. HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer.
Wang J; He C; Gao P; Wang S; Lv R; Zhou H; Zhou Q; Zhang K; Sun J; Fan C; Ding G; Lan F
Oncogene; 2020 Feb; 39(6):1335-1346. PubMed ID: 31636385
[TBL] [Abstract][Full Text] [Related]
14. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
[TBL] [Abstract][Full Text] [Related]
15. NSD2 is a conserved driver of metastatic prostate cancer progression.
Aytes A; Giacobbe A; Mitrofanova A; Ruggero K; Cyrta J; Arriaga J; Palomero L; Farran-Matas S; Rubin MA; Shen MM; Califano A; Abate-Shen C
Nat Commun; 2018 Dec; 9(1):5201. PubMed ID: 30518758
[TBL] [Abstract][Full Text] [Related]
16. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.
Han X; Piao L; Yuan X; Wang L; Liu Z; He X
Int J Med Sci; 2019; 16(10):1404-1411. PubMed ID: 31692936
[No Abstract] [Full Text] [Related]
19. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.
Yuan H; Han Y; Wang X; Li N; Liu Q; Yin Y; Wang H; Pan L; Li L; Song K; Qiu T; Pan Q; Chen Q; Zhang G; Zang Y; Tan M; Zhang J; Li Q; Wang X; Jiang J; Qin J
Cancer Cell; 2020 Sep; 38(3):350-365.e7. PubMed ID: 32619406
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of tumour NSD2 expression in advanced prostate cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Garstka N; Grubmüller B; Haitel A; Enikeev DV; Glybochko PV; Kramer G; Susani M; Shariat SF
Biomarkers; 2020 May; 25(3):268-273. PubMed ID: 32091270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
